S&P 500 Futures
(0.21%) 5 142.50 points
Dow Jones Futures
(0.17%) 38 505 points
Nasdaq Futures
(0.30%) 17 899 points
Oil
(-0.31%) $83.59
Gas
(1.82%) $1.958
Gold
(0.17%) $2 351.10
Silver
(0.57%) $27.69
Platinum
(0.94%) $930.75
USD/EUR
(-0.09%) $0.934
USD/NOK
(-0.21%) $11.00
USD/GBP
(-0.20%) $0.799
USD/RUB
(1.29%) $93.06

リアルタイムの更新: Johnson & Johnson [JNJ.DE]

取引所: XETRA セクター: Pharmaceuticals 産業: Drug Manufacturers—General
最終更新日時29 4月 2024 @ 17:29

-0.47% 136.56

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 17:29):

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide...

Stats
本日の出来高 341.00
平均出来高 3 218.00
時価総額 329.08B
EPS €0 ( 2024-04-15 )
次の収益日 ( €0 ) 2024-07-16
Last Dividend €1.190 ( 2023-08-25 )
Next Dividend €0 ( N/A )
P/E 19.71
ATR14 €0.113 (0.08%)

ボリューム 相関

長: 0.00 (neutral)
短: 0.75 (moderate)
Signal:(41.313) Neutral

Johnson & Johnson 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Johnson & Johnson 相関 - 通貨/商品

The country flag 0.67
( moderate )
The country flag 0.16
( neutral )
The country flag 0.00
( neutral )
The country flag 0.51
( weak )
The country flag 0.01
( neutral )
The country flag -0.71
( moderate negative )

Johnson & Johnson 財務諸表

Annual 2023
収益: €85.16B
総利益: €58.61B (68.82 %)
EPS: €13.88
FY 2023
収益: €85.16B
総利益: €58.61B (68.82 %)
EPS: €13.88
FY 2022
収益: €94.94B
総利益: €63.85B (67.26 %)
EPS: €6.86
FY 2021
収益: €93.78B
総利益: €63.92B (68.16 %)
EPS: €7.93

Financial Reports:

No articles found.

Johnson & Johnson Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€1.130
(N/A)
€1.130
(N/A)
€1.130
(N/A)
€1.190
(N/A)
€1.190
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Johnson & Johnson Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 3.76 - low (25.10%) | Divividend Growth Potential Score: 5.82 - Stable (16.47%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.415 2008-02-22
Last Dividend €1.190 2023-08-25
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 65 --
Total Paid Out €56.18 --
Avg. Dividend % Per Year 0.00% --
Score 3.59 --
Div. Sustainability Score 3.76
Div.Growth Potential Score 5.82
Div. Directional Score 4.79 --
Next Divdend (Est)
(2024-07-01)
€1.211 Estimate 22.50 %
Dividend Stability
0.60 Above Average
Dividend Score
3.59
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LOM.DE Ex Dividend Knight 2023-08-31 Quarterly 0 0.00%
2GB.DE Ex Dividend Junior 2023-06-14 Annually 0 0.00%
V6C.DE Ex Dividend Junior 2023-06-01 Annually 0 0.00%
ELG.DE Ex Dividend Knight 2023-05-11 Annually 0 0.00%
NTH.DE Ex Dividend Knight 2023-08-25 Quarterly 0 0.00%
AEIN.DE Ex Dividend Knight 2023-06-14 Annually 0 0.00%
GOB.DE Ex Dividend Knight 2023-06-12 Sporadic 0 0.00%
PSQ.F Ex Dividend Knight 2023-08-23 Semi-Annually 0 0.00%
BLQA.DE Ex Dividend Knight 2023-09-07 Quarterly 0 0.00%
INH.DE Ex Dividend Knight 2023-05-18 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.4531.5000.9491.424[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.5721.5004.767.14[0.1 - 1]
payoutRatioTTM0.218-1.0007.82-7.82[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM44.511.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM8.032.007.3210.00[0 - 30]
freeCashFlowPerShareTTM6.322.006.8410.00[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.6871.0001.8901.890[0.2 - 0.8]
operatingProfitMarginTTM0.2731.0006.546.54[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score3.76

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM8.831.0009.210[1 - 100]
returnOnEquityTTM0.5722.506.637.14[0.1 - 1.5]
freeCashFlowPerShareTTM6.322.007.8910.00[0 - 30]
dividendYielPercentageTTM3.231.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM8.032.007.3210.00[0 - 30]
payoutRatioTTM0.2181.5007.82-7.82[0 - 1]
pegRatioTTM-0.3031.500-5.350[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2181.0007.050[0.1 - 0.5]
Total Score5.82

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。